Work Here?
Azurity Pharmaceuticals
Work Here?
Develops specialized formulations of medicines
Azurity Pharmaceuticals
Work Here?
Develops specialized formulations of medicines
About Azurity Pharmaceuticals
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Growth Equity (Venture Capital)
Total Funding
$182.2M
Headquarters
Woburn, Massachusetts
Founded
2000
Overview
Azurity Pharmaceuticals develops specialized formulations of existing medicines to meet the needs of patients who are often overlooked by traditional pharmaceutical companies. Their products include oral suspensions and other forms that are easier to administer, particularly for those who have difficulty swallowing pills or need precise dosing. This focus on creating accessible and effective medications enhances patient compliance and addresses gaps in the healthcare market. Azurity serves healthcare providers, hospitals, and pharmacies, generating revenue through the sale of FDA-approved proprietary medicines. Their goal is to improve patient outcomes by providing high-quality, innovative medicines tailored to specific medical conditions.
Simplify's Take
What believers are saying
- Growing demand for personalized medicine aligns with Azurity's innovative dose forms.
- Acquisitions enhance Azurity's R&D capabilities, accelerating new drug development.
- FDA's focus on patient-friendly formulations supports Azurity's strategic direction.
What critics are saying
- Zenzedi recall may harm Azurity's reputation for quality and safety.
- Covis acquisition could lead to integration challenges and operational disruptions.
- Azmiro launch faces competition in the testosterone replacement therapy market.
What makes Azurity Pharmaceuticals unique
- Azurity focuses on innovative dose forms for overlooked patient needs.
- The company offers FDA-approved proprietary medicines across diverse therapeutic areas.
- Azurity's acquisition of Covis expands its global reach and product portfolio.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$182.2M
Above
Industry Average
Funded Over
0 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Hybrid Work Options
Professional Development Budget
Tuition Reimbursement
Wellness Program
Company News
WOBURN, Mass., March 14, 2025 /PRNewswire/ -- Azurity Pharmaceuticals ("Azurity") announced today the successful completion of its acquisition of Covis Group S.à r.l. ("Covis") from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity.This strategic acquisition reinforces Azurity's leadership in branded pharmaceuticals, harnessing the complementary strengths of both companies across multiple complex dosage forms and therapeutic areas. By combining expertise and resources, Azurity strengthens its ability to deliver medicines to overlooked patients on a global scale.Strategic Benefits of the Acquisition:Expanded Therapeutic Portfolio – The integration of Covis' product portfolio and pipeline enhances Azurity's offerings across ten complex dosage forms and nine key therapeutic areas, including cardiovascular, respiratory, central nervous system, endocrinology, gastrointestinal, hematology, immunology, anti-infectives, and oncology.– The integration of Covis' product portfolio and pipeline enhances Azurity's offerings across ten complex dosage forms and nine key therapeutic areas, including cardiovascular, respiratory, central nervous system, endocrinology, gastrointestinal, hematology, immunology, anti-infectives, and oncology. Global Footprint – The acquisition strengthens Azurity's global footprint, expanding its commercial presence to over 50 countries and enabling greater patient accessibility to life-changing treatments. Azurity and its subsidiaries will employ more than 800 colleagues across North America , Europe and Asia.– The acquisition strengthens Azurity's global footprint, expanding its commercial presence to over 50 countries and enabling greater patient accessibility to life-changing treatments
Azurity Pharmaceuticals completes acquisition of Covis Pharma.
WOBURN, Mass., Dec. 12, 2024 /PRNewswire/ -- Azurity Pharmaceuticals announced today the availability of Azmiro™, the first and only FDA-approved prefilled testosterone cypionate injection. Azmiro is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. "Azurity's purpose is to serve overlooked patients by developing innovative dose forms and formulations to serve unmet needs," said Richard Blackburn, CEO of Azurity Pharmaceuticals. "The commercial availability of Azmiro offers a convenient prefilled option for healthcare providers administering testosterone to patients.". Testosterone cypionate intramuscular injections are commonly used as a testosterone replacement therapy for patients with low testosterone by drawing up testosterone cypionate doses from a vial, then administering with a syringe
WOBURN, Mass., Dec. 12, 2024 /PRNewswire/ - Azurity Pharmaceuticals announced today the availability of Azmiro(TM), the first and only FDA-approved prefilled testosterone cypionate injection.
WOBURN, Mass., May 6, 2024 /PRNewswire/ -- Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved Myhibbin™, the only ready-to-use mycophenolate mofetil oral suspension. Mycophenolate mofetil is an antimetabolite immunosuppressant used to protect a donated organ from being rejected from the body's immune response. In 2023, there were over 46,000 transplants in the US and these patients need to take medication every day to fight against rejection. Myhibbin is indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart, or liver transplants, in combination with other immunosuppressants."We are very pleased that adult and pediatric organ transplant recipients will soon have access to the only FDA-approved ready-to-use oral liquid formulation of mycophenolate," said Richard Blackburn, CEO of Azurity Pharmaceuticals. "Patients are our priority, and our purpose is to bring them new formulations that help them benefit from established medicines
Azurity Pharmaceuticals is Hiring for 15 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Azurity Pharmaceuticals
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Growth Equity (Venture Capital)
Total Funding
$182.2M
Headquarters
Woburn, Massachusetts
Founded
2000
Azurity Pharmaceuticals is Hiring for 15 Jobs on Simplify!
Find jobs on Simplify and start your career today